Challenging Cases in Diffuse Large B-cell Lymphoma (DLBCL) - Drs. Gilles Salles & Matt Lunning

In this episode of the Oncology Brothers podcast, we tackled two real-world challenging cases in diffuse large B-cell lymphoma (DLBCL) alongside two lymphoma experts — Dr. Matthew Lunning from the University of Nebraska and Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. The central question: when faced with relapsed or transformed aggressive B-cell lymphoma, how do you choose between CAR-T cell therapy and bispecific antibodies, and how do you get patients through this safely? Key topics discussed included:The role of CAR-T cell therapy in early relapsed DLBCL based on ZUMA-7 and TRANSFORM trial data, and practical strategies for bridging and holding therapy pre- and post-apheresis to safely deliver treatment.A comparison of axicabtagene ciloleucel versus lisocabtagene maraleucel in terms of efficacy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) rates, and outpatient feasibility.Management of transformed follicular lymphoma to double-hit DLBCL in the third-line setting, including the role of glofitamab, mosunetuzumab, polatuzumab, and epcoritamab as bridges to CAR-T cell therapy.The importance of early partnership between community oncologists and tertiary care centers to ensure patients access CAR-T and bispecific therapies in a timely manner.Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media:X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Join us for this expert discussion on navigating the complex treatment landscape of relapsed and transformed aggressive B-cell lymphoma. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!#DLBCL, #CARTTherapy, #BispecificAntibodies, #Hematology, #OncologyBrothers